Ranked by evidence, the best peptides for wound healing are still experimental: no peptide is FDA-approved for wounds, and the most-studied candidates had mixed or negative trials. Pexiganan cream failed two phase 3 trials, and a larger LL-37 leg ulcer trial found no overall benefit.[5][7] The approved option, becaplermin gel for certain diabetic foot ulcers, is a growth-factor protein used on top of good wound care, not a replacement for it.[3]
Most chronic wounds heal when the cause is treated. This guide ranks peptides by evidence after covering the care that works. It is part of our healing peptides hub.
Evidence-graded table
| Peptide or drug | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Becaplermin gel (PDGF protein, not a small peptide) | FDA-approved for this use | Complete closure 50% vs 35% on placebo gel in diabetic foot ulcers[2] | Approved for deep diabetic neuropathic foot ulcers[3] | Not applicable |
| Pexiganan cream | Human RCTs (negative vs placebo) | Matched an oral antibiotic, then failed two placebo-controlled phase 3 trials[4][5] | Not approved | Not applicable |
| LL-37 | Human RCTs (mixed) | Small trial positive; 148-patient trial no overall benefit[6][7] | Not approved | LL-37 |
| Peceleganan spray | Human RCTs (open-label) | Higher clinical efficacy than silver sulfadiazine for infected wounds[9] | Not approved in the US | Not applicable |
| Thymosin beta-4 gel | Small human studies | Phase 2 ulcer trials hinted at faster healing[10][11] | Not approved | TB-500 |
| GHK-Cu | Small human studies (mixed) | Faster diabetic ulcer closure in one trial; no better than placebo in leg ulcers[13][14] | Not approved as a drug | GHK-Cu |
| BPC-157 | Animal or lab only | Rat wound and tendon studies only | Not approved | BPC-157 |
Start with wound care that works
Chronic wounds stall for a reason, and treating that reason matters far more than any topical product.
- Diabetic foot ulcers: pressure offloading, sharp debridement, infection control and blood sugar control. The International Working Group on the Diabetic Foot made 29 recommendations in 2023, including conditional support for some advanced dressings and oxygen therapies, while noting the evidence remains poor overall.[1]
- Venous leg ulcers: compression, dressings, removal of dead tissue and infection control are standard care.[10]
- Pressure injuries: relieving pressure, nutrition and moisture management.
Becaplermin (Regranex) is the one FDA-approved growth-factor gel. In its phase 3 trial, 50% of diabetic foot ulcers fully closed versus 35% with placebo gel.[2] Its label limits it to deep diabetic neuropathic ulcers with good blood supply, as an add-on to debridement, offloading and infection control. The label also warns that malignancies distant from the application site have been reported.[3]
Antimicrobial peptides: pexiganan, LL-37 and peceleganan
Pexiganan, based on a frog-skin peptide, matched oral ofloxacin for mildly infected diabetic foot ulcers in trials of 835 patients, with clinical improvement in 85% to 90% of both groups.[4] But in 2016 its OneStep-1 and OneStep-2 trials in 389 patients found it no better than a placebo cream added to standard wound care.[5]
LL-37 is the body’s own antimicrobial peptide. In a first trial of 34 people with hard-to-heal venous leg ulcers, the two lower doses healed faster than placebo, while the highest dose did not.[6] The larger HEAL LL-37 trial in 148 patients found no significant healing improvement overall; a post hoc look suggested benefit only in large wounds.[7] In diabetic foot ulcers, LL-37 cream increased healthy granulation tissue over four weeks.[8]
Peceleganan spray beat 1% silver sulfadiazine cream for skin wound infections in a trial of 570 patients (clinical efficacy 90.4% vs 78.7% on day 8), but the trial was open-label and did not use a placebo.[9]
Our antimicrobial peptides for wound care guide covers these trials and peptide dressings in more depth.
Thymosin beta-4: hints from phase 2
Thymosin beta-4 is a natural protein that helps skin cells migrate into a wound. A phase 2 trial of a topical gel in 73 people with venous ulcers found it acceptably safe and suggested the 0.03% dose might speed healing.[10] A review of two phase 2 trials, in venous and pressure ulcers, reported healing almost a month faster among patients who healed.[11][12] No phase 3 results have led to approval.
The TB-500 sold online is a short fragment, not the full protein, and has no human data. FDA said it found no human exposure data for it.[15] See our TB-500 dosage guide.
GHK-Cu: one positive trial, one negative
GHK-Cu, a copper-binding tripeptide, was tested decades ago as a wound gel. In a multicenter trial with standardized care, it increased closure of diabetic plantar ulcers (98.5% vs 60.8% median closure).[13] In an 86-patient venous ulcer trial, it did no better than placebo, while silver sulfadiazine did better than both.[14] See our GHK-Cu research guide.
Why wound peptides keep falling short
The pattern across these trials is familiar: promising lab and early results, then disappointing larger trials. A few reasons help explain it.
- Strong control groups. In modern trials, everyone gets good standard care. In HEAL LL-37, the placebo group also had compression therapy,[7] and in the pexiganan phase 3 trials, both arms had standard local wound care.[5] Beating good care is much harder than beating no care.
- Hostile wound beds. Chronic wounds are full of enzymes and bacteria that can break down short peptides before they act.
- Small, short studies. Many peptide trials ran for four weeks or less, with dozens rather than hundreds of patients.
That is why an “it worked in rats” claim says little about a real, months-old ulcer.
BPC-157: no human wound trials
BPC-157 is widely promoted for healing, but its wound evidence comes from animals. There are no controlled human wound trials; our BPC-157 clinical trials guide lists the few human reports.
Questions for your wound care team
- What is stopping this wound from healing, and how are we treating that?
- Do I need offloading, compression or a vascular check?
- Am I a candidate for becaplermin or an advanced dressing?
- How will we know if the wound is infected?
If your wound is from surgery, see our guide to peptides for post-surgery recovery, and for scars after healing, peptides for scars.
